Background: Neoadjuvant chemotherapy (NACT) is used in breast cancer to evaluate the response to treatment. We examined the usefulness of breast magnetic resonance imaging (MRI) in the evaluation of tumor response after NACT.
Methods: Breast MRIs of 87 women with MRI after NACT were reviewed. The Spearman coefficient was used for estimating the correlation between MRI and pathologic tumor sizes (ypTs).
Results: The median age was 50 years (range 25 to 83 years). The median MRI size was 1.25 cm (range 0 to 10 cm). The median ypT was 1.20 cm (range 0 to 10.4 cm). The Spearman coefficient between MRI and ypT was .78 (95% confidence interval, .67 to .85; P < .0001). MRI was found to have a positive predictive value of 92% and a negative predictive value of 64% for residual in-breast disease. The sensitivity and specificity of MRI were 86% and 77%, respectively.
Conclusions: MRI correlates well with the final pathology and can be a useful modality to predict residual disease after NACT and aid in surgical planning.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.amjsurg.2013.02.006 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Tumour volume analysis applied to imaging and histological examinations in breast cancer.
Eur J Surg Oncol
January 2025
Imperial College Healthcare Trust, Fulham Palace Road, London, W6 8RF, England, UK. Electronic address:
Purpose: Response Evaluation Criteria in Solid Tumours (RECIST) determines partial response (PR) and progressive disease (PD) as a 30 % reduction and 20 % increase in the longest diameter (LD), respectively. Tumour volume analysis (TVA) utilises three diameters to calculate response parameters.
Patients And Methods: We conducted a pilot investigation of patients who underwent neoadjuvant breast cancer treatment and evaluation using RECIST with LD measurements and TVA with three diametric measurements, using the parameters PR (>30 % tumour regression), PD (>20 % tumour growth), and intermediate stable disease (SD).
The Role of Positron Emission Tomography Imaging in Breast Implant Illness.
Plast Reconstr Surg Glob Open
January 2025
From the Section General Internal Medicine, Department of Internal Medicine, Amsterdam Public Health Research Institute, Amsterdam University Medical Centers, Amsterdam, The Netherlands.
Background: Explantation often alleviates symptoms in women with breast implant illness. However, persistent complaints in some cases may be linked to persistent silicone-induced inflammation from residual silicone particles. Positron emission tomography (PET) imaging could potentially detect this inflammation.
View Article and Find Full Text PDFPrediction of axillary nodal burden using preoperative magnetic resonance imaging scoring in patients with clinically node-negative breast cancer: a retrospective cohort study.
Gland Surg
December 2024
Department of Radiology, King Chulalongkorn Memorial Hospital, Bangkok, Thailand.
Background: Axillary lymph node metastasis (ALNM) is a significant predictor of overall patient survival; thus, precise evaluation of ALNM is essential for staging breast cancer, informing multimodal treatment strategies, and ensuring optimal patient care. This study aimed to establish a magnetic resonance imaging (MRI) scoring system for predicting extensive axillary nodal metastasis in patients with clinically node-negative breast cancer derived from preoperative breast and axillary MRI.
Methods: This study included 226 patients with clinically node-negative breast cancer who underwent preoperative breast and axillary MRI between January 1, 2010 and December 31, 2020 at King Chulalongkorn Memorial Hospital.
Development and validation of a radiomics-based nomogram for predicting two subtypes of HER2-negative breast cancer.
Gland Surg
December 2024
Medical Imaging Department, Affiliated Hospital of Jining Medical University, Jining, China.
Background: Breast cancer is the most common malignant tumor among women, with an increasing incidence each year. The subtypes of human epidermal growth factor receptor 2 (HER2)-negative breast cancer, classified as HER2-low and HER2-zero based on HER2 receptor expression, show differences in clinical characteristics, therapeutic approaches, and prognoses. Distinguishing between these subtypes is clinically valuable as it can impact treatment strategies, including the use of next-generation antibody-drug conjugates (ADCs) targeting HER2-low tumors.
View Article and Find Full Text PDFPatient perspective: Is intensive screening of women at high risk of breast cancer evidence-based medicine or ?
Womens Health (Lond)
January 2025
Department of Pharmacy Practice, Midwestern University College of Pharmacy, Glendale Campus, Glendale, AZ, USA.
In 2023, a breast cancer risk assessment and a subsequent positive test for the BRCA-2 genetic mutation brought me to the uncomfortable intersection of a longstanding career as an advocate for high-quality medical evidence to support shared patient-provider decision making and a new role as a high-risk patient. My search for studies of available risk-management options revealed that the most commonly recommended approach for women with a ⩾20% lifetime breast cancer risk, intensive screening including annual mammography and/or magnetic resonance imaging beginning at age 25-40 years, was supported only by cancer-detection statistics, with almost no evidence on patient-centered outcomes-mortality, physical and psychological morbidity, or quality of life-compared with standard screening or a surgical alternative, bilateral risk-reducing mastectomy. In this commentary, I explore parallels between the use of the intensive screening protocol and another longstanding women's health recommendation based on limited evidence, the use of hormone therapy (HT) for postmenopausal chronic disease prevention, which was sharply curtailed after the publication of the groundbreaking Women's Health Initiative trial in 2002.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!